
ANI Pharmaceuticals, Inc.: shareholders and insiders
Price
$69.13
November 19, 2026Market cap $1.6B
What Ploutos Investor adds for ANI Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 20, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$14M
11 people
From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan46%
- The rest54%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 20, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $14M by 10 people
- 2025: no buys, sold $312.7K by 3 people
- 2026: no buys, sold $14M by 10 people
- Nov 18, 2026Nikhil LalwaniPRESIDENT & CEOKind10b5-1
- Nov 16, 2026Nikhil LalwaniPRESIDENT & CEOKind10b5-1
- Nov 13, 2026Meredith CookSR. VP, GENERAL COUNSEL & SEC.Kind10b5-1
- Oct 29, 2026Stephen P. CareySVP & CFOKind10b5-1
- Oct 15, 2026Nikhil LalwaniPRESIDENT & CEOKind10b5-1
- Oct 13, 2026Meredith CookSR. VP, GENERAL COUNSEL & SEC.Kind10b5-1
- Sep 29, 2026Stephen P. CareySVP & CFOKind10b5-1
- Sep 15, 2026Nikhil LalwaniPRESIDENT & CEOKind10b5-1
- Sep 14, 2026Meredith CookSR. VP, GENERAL COUNSEL & SEC.Kind10b5-1
- Sep 11, 2026Jeanne ThomaDirectorKind10b5-1
- Aug 31, 2026Stephen P. CareySVP & CFOKind10b5-1
- Aug 25, 2026Nikhil LalwaniPRESIDENT & CEOKind10b5-1
- Aug 19, 2026Henry O GosebruchDirectorKind
- Aug 13, 2026Meredith CookSR. VP, GENERAL COUNSEL & SEC.Kind10b5-1
- Aug 10, 2026Ori GutwergSVP, GENERICSKind
- Jul 29, 2026Stephen P. CareySVP & CFOKind10b5-1
- Jul 18, 2026Meredith CookSR. VP, GENERAL COUNSEL & SEC.Kind
- Jul 13, 2026Meredith CookSR. VP, GENERAL COUNSEL & SEC.Kind10b5-1
- Jul 2, 2026Stephen P. CareySVP & CFOKind10b5-1
- Jul 2, 2026Stephen P. CareySVP & CFOKind10b5-1
- Jun 29, 2026Stephen P. CareySVP & CFOKind10b5-1
- Jun 12, 2026Meredith CookSR. VP, GENERAL COUNSEL & SEC.Kind10b5-1
- Jun 8, 2026Thomas HaugheyDirectorKind10b5-1
- Jun 5, 2026Stephen P. CareySVP & CFOKind10b5-1
- Jun 5, 2026Stephen P. CareySVP & CFOKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Nikhil LalwaniPRESIDENT & CEO | 10b5-1 | 4,082 | $71.16 | $290.5K | Form 4 |
| Nov 16, 2026 | Nikhil LalwaniPRESIDENT & CEO | 10b5-1 | 1,318 | $71.40 | $94.1K | Form 4 |
| Nov 13, 2026 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | 10b5-1 | 500 | $70.80 | $35.4K | Form 4 |
| Oct 29, 2026 | Stephen P. CareySVP & CFO | 10b5-1 | 2,850 | $72.87 | $207.7K | Form 4 |
| Oct 15, 2026 | Nikhil LalwaniPRESIDENT & CEO | 10b5-1 | 5,400 | $71.89 | $388.2K | Form 4 |
| Oct 13, 2026 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | 10b5-1 | 500 | $73.59 | $36.8K | Form 4 |
| Sep 29, 2026 | Stephen P. CareySVP & CFO | 10b5-1 | 2,850 | $73.00 | $208.1K | Form 4 |
| Sep 15, 2026 | Nikhil LalwaniPRESIDENT & CEO | 10b5-1 | 5,400 | $71.00 | $383.4K | Form 4 |
| Sep 14, 2026 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | 10b5-1 | 500 | $70.79 | $35.4K | Form 4 |
| Sep 11, 2026 | Jeanne ThomaDirector | 10b5-1 | 1,000 | $71.53 | $71.5K | Form 4 |
| Aug 31, 2026 | Stephen P. CareySVP & CFO | 10b5-1 | 2,850 | $72.80 | $207.5K | Form 4 |
| Aug 25, 2026 | Nikhil LalwaniPRESIDENT & CEO | 10b5-1 | 5,400 | $74.30 | $401.2K | Form 4 |
| Aug 19, 2026 | Henry O GosebruchDirector | 6,662 | – | – | Form 4 | |
| Aug 13, 2026 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | 10b5-1 | 500 | $75.48 | $37.7K | Form 4 |
| Aug 10, 2026 | Ori GutwergSVP, GENERICS | 3,162 | $77.00 | $243.5K | Form 4 | |
| Jul 29, 2026 | Stephen P. CareySVP & CFO | 10b5-1 | 2,850 | $81.36 | $231.9K | Form 4 |
| Jul 18, 2026 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | 2,466 | $79.20 | $195.3K | Form 4 | |
| Jul 13, 2026 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | 10b5-1 | 500 | $81.84 | $40.9K | Form 4 |
| Jul 2, 2026 | Stephen P. CareySVP & CFO | 10b5-1 | 3,313 | $49.51 | $164.0K | Form 4 |
| Jul 2, 2026 | Stephen P. CareySVP & CFO | 10b5-1 | 3,313 | $86.00 | $284.9K | Form 4 |
| Jun 29, 2026 | Stephen P. CareySVP & CFO | 10b5-1 | 2,850 | $84.12 | $239.7K | Form 4 |
| Jun 12, 2026 | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | 10b5-1 | 500 | $82.03 | $41.0K | Form 4 |
| Jun 8, 2026 | Thomas HaugheyDirector | 10b5-1 | 2,000 | $80.88 | $161.8K | Form 4 |
| Jun 5, 2026 | Stephen P. CareySVP & CFO | 10b5-1 | 3,312 | $49.51 | $164.0K | Form 4 |
| Jun 5, 2026 | Stephen P. CareySVP & CFO | 10b5-1 | 3,312 | $80.00 | $265.0K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 9, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by ANIP's officers and directors from 2006 up to November 19, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class12.8%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12.8% | 2.90M | Jul 27, 20262 filings since Oct 17, 2025 | 13G/A |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Millennium Mgmt (Englander)In the quarter-52%
- Citadel Advisors (Griffin)In the quarter+14%
- D.E. ShawIn the quarter-37%
- Renaissance TechnologiesIn the quarter-72%
- AQR CapitalIn the quarter-2.9%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Millennium Mgmt (Englander) | 243.1K | -52% | $18M | 0.01% |
| Citadel Advisors (Griffin) | 109.3K | +14% | $7.9M | 0.00% |
| D.E. Shaw | 109.5K | -37% | $8.0M | 0.00% |
| Renaissance Technologies | 18.0K | -72% | $1.3M | 0.00% |
| AQR Capital | 28.6K | -2.9% | $2.1M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 15.4% of its shares outstanding were held short, -0.6% since the report before.
- Shares held short
- 3.47M
- 15.4%
- Since the report before3.49M on Sep 30, 2026
- -0.6%
- 10.1
- 343.8K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 91%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 423.4K
- Nov 15, 2023: Shares held short 376.8K
- Nov 30, 2023: Shares held short 401.7K
- Dec 15, 2023: Shares held short 399.7K
- Dec 29, 2023: Shares held short 264.0K
- Jan 12, 2024: Shares held short 223.9K
- Jan 31, 2024: Shares held short 242.2K
- Feb 15, 2024: Shares held short 213.4K
- Feb 29, 2024: Shares held short 249.1K
- Mar 15, 2024: Shares held short 261.6K
- Mar 28, 2024: Shares held short 197.0K
- Apr 15, 2024: Shares held short 213.5K
- Apr 30, 2024: Shares held short 229.9K
- May 15, 2024: Shares held short 204.4K
- May 31, 2024: Shares held short 339.1K
- Jun 14, 2024: Shares held short 376.5K
- Jun 28, 2024: Shares held short 369.0K
- Jul 15, 2024: Shares held short 390.0K
- Jul 31, 2024: Shares held short 309.4K
- Aug 15, 2024: Shares held short 1.67M
- Aug 30, 2024: Shares held short 2.42M
- Sep 13, 2024: Shares held short 2.22M
- Sep 30, 2024: Shares held short 2.27M
- Oct 15, 2024: Shares held short 2.05M
- Oct 31, 2024: Shares held short 2.16M
- Nov 15, 2024: Shares held short 2.11M
- Nov 29, 2024: Shares held short 1.84M
- Dec 13, 2024: Shares held short 2.35M
- Dec 31, 2024: Shares held short 2.15M
- Jan 15, 2025: Shares held short 2.29M
- Jan 31, 2025: Shares held short 2.26M
- Feb 14, 2025: Shares held short 2.56M
- Feb 28, 2025: Shares held short 2.56M
- Mar 14, 2025: Shares held short 2.58M
- Mar 31, 2025: Shares held short 2.64M
- Apr 15, 2025: Shares held short 2.36M
- Apr 30, 2025: Shares held short 2.00M
- May 15, 2025: Shares held short 1.86M
- May 30, 2025: Shares held short 1.90M
- Jun 13, 2025: Shares held short 2.01M
- Jun 30, 2025: Shares held short 2.01M
- Jul 15, 2025: Shares held short 2.13M
- Jul 31, 2025: Shares held short 2.21M
- Aug 15, 2025: Shares held short 2.20M
- Aug 29, 2025: Shares held short 2.04M
- Sep 15, 2025: Shares held short 2.05M
- Sep 30, 2025: Shares held short 2.33M
- Oct 15, 2025: Shares held short 2.38M
- Oct 31, 2025: Shares held short 2.50M
- Nov 14, 2025: Shares held short 2.49M
- Nov 28, 2025: Shares held short 2.85M
- Dec 15, 2025: Shares held short 2.67M
- Dec 31, 2025: Shares held short 2.96M
- Jan 15, 2026: Shares held short 2.94M
- Jan 30, 2026: Shares held short 3.47M
- Feb 13, 2026: Shares held short 3.43M
- Feb 27, 2026: Shares held short 3.53M
- Mar 13, 2026: Shares held short 3.60M
- Mar 31, 2026: Shares held short 3.58M
- Apr 15, 2026: Shares held short 3.49M
- Apr 30, 2026: Shares held short 3.56M
- May 15, 2026: Shares held short 3.62M
- May 29, 2026: Shares held short 3.32M
- Jun 15, 2026: Shares held short 3.20M
- Jun 30, 2026: Shares held short 3.44M
- Jul 15, 2026: Shares held short 3.37M
- Jul 31, 2026: Shares held short 2.33M
- Aug 14, 2026: Shares held short 3.42M
- Aug 31, 2026: Shares held short 3.36M
- Sep 15, 2026: Shares held short 2.49M
- Sep 30, 2026: Shares held short 3.49M
- Oct 15, 2026: Shares held short 3.47M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading49.3% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 49.3% of the shares in the reported trades were short sales, against 61.9% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 49.3%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 61.9%
- Change
- -12.6 pts
- Short sales a dayon average, of 160.7K shares
- 79.2K
- More than atof 3,666 US-listed companies, same days
- 46%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 45.2%
- Oct 14, 2026: Short sales 70.7%
- Oct 15, 2026: Short sales 44.3%
- Oct 16, 2026: Short sales 59.4%
- Oct 19, 2026: Short sales 58.1%
- Oct 20, 2026: Short sales 45.4%
- Oct 21, 2026: Short sales 40.2%
- Oct 22, 2026: Short sales 74.8%
- Oct 23, 2026: Short sales 64.5%
- Oct 26, 2026: Short sales 54.4%
- Oct 27, 2026: Short sales 70%
- Oct 28, 2026: Short sales 67.2%
- Oct 29, 2026: Short sales 72.8%
- Oct 30, 2026: Short sales 76.6%
- Nov 2, 2026: Short sales 56.5%
- Nov 3, 2026: Short sales 53.3%
- Nov 4, 2026: Short sales 57.4%
- Nov 5, 2026: Short sales 36.7%
- Nov 6, 2026: Short sales 46.1%
- Nov 9, 2026: Short sales 40.9%
- Nov 10, 2026: Short sales 53.4%
- Nov 11, 2026: Short sales 37.1%
- Nov 12, 2026: Short sales 61.4%
- Nov 13, 2026: Short sales 65.5%
- Nov 16, 2026: Short sales 61.7%
- Nov 17, 2026: Short sales 59.9%
- Nov 18, 2026: Short sales 54.2%
- Nov 19, 2026: Short sales 65.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPSDirectly–
- Nikhil LalwaniPRESIDENT & CEODirectly328.3K
- Stephen P. CareySVP & CFODirectly166.1K
- Chad GassertSVP - CORP. DEV. & STRATEGYDirectly–
- James G. MarkenSVP OPS & PROD DEVDirectly124.5K
- Christopher MutzHEAD OF RARE DISEASEDirectly91.3K
- Ori GutwergSVP, GENERICSDirectly75.5K
- Meredith CookSR. VP, GENERAL COUNSEL & SEC.Directly72.9K
- Krista DavisSVP, CHIEF HR OFFICERDirectly51.9K
- Thomas HaugheyDirectorDirectly38.9K
- Patrick D WalshDirectorDirectly38.4K
- Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDSDirectly38.3K
- Renee P TannenbaumDirectorDirectly29.5K
- Antonio R PeraDirectorDirectly27.0K
- Jeanne ThomaDirectorDirectly26.8K
- Matthew J LeonardDirectorDirectly11.2K
- Henry O GosebruchDirectorDirectly6,662
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS | – | 431.9K | Aug 21, 2025 | Form 4 |
| Nikhil LalwaniPRESIDENT & CEO | 328.3K | – | Nov 18, 2026 | Form 4 |
| Stephen P. CareySVP & CFO | 166.1K | – | Oct 29, 2026 | Form 4 |
| Chad GassertSVP - CORP. DEV. & STRATEGY | – | 158.5K | Nov 13, 2025 | Form 4 |
| James G. MarkenSVP OPS & PROD DEV | 124.5K | – | Mar 7, 2024 | Form 4 |
| Christopher MutzHEAD OF RARE DISEASE | 91.3K | – | Mar 13, 2026 | Form 4 |
| Ori GutwergSVP, GENERICS | 75.5K | – | Aug 10, 2026 | Form 4 |
| Meredith CookSR. VP, GENERAL COUNSEL & SEC. | 72.9K | – | Nov 13, 2026 | Form 4 |
| Krista DavisSVP, CHIEF HR OFFICER | 51.9K | – | Mar 9, 2026 | Form 4 |
| Thomas HaugheyDirector | 38.9K | – | Jun 8, 2026 | Form 4 |
| Patrick D WalshDirector | 38.4K | – | May 13, 2026 | Form 4 |
| Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | 38.3K | – | May 12, 2026 | Form 4 |
| Renee P TannenbaumDirector | 29.5K | – | May 21, 2026 | Form 4 |
| Antonio R PeraDirector | 27.0K | – | May 21, 2026 | Form 4 |
| Jeanne ThomaDirector | 26.8K | – | Sep 11, 2026 | Form 4 |
| Matthew J LeonardDirector | 11.2K | – | May 21, 2026 | Form 4 |
| Henry O GosebruchDirector | 6,662 | – | Aug 19, 2026 | Form 4 |
A lower bound: it counts only the 17 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund0.34%
- CALFPacer US Small Cap Cash Cows 100 ETFWeight in the fund0.17%
- IJTiShares S&P Small-Cap 600 Growth ETFWeight in the fund0.16%
- AVUVAvantis U.S. Small Cap Value ETFWeight in the fund0.15%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.10%
- IJRiShares Core S&P Small-Cap ETFWeight in the fund0.08%
- SPSMState Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETFWeight in the fund0.08%
- IWMiShares Russell 2000 ETFWeight in the fund0.05%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.05%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.04%
23 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 270
- Q4 2025: Managers 286
- Q1 2026: Managers 284
- Q2 2026: Managers 307
Institutional investors by quarter
The fund managers holding ANIP, quarter by quarter, from Q2 2013 to Q2 2025, 49 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 307 managers held 22.98M shares, worth $1.9B. During the quarter 52 opened a position, 29 closed one, 116 added and 86 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+7.7%
- Soleus Capital ManagementIn the quarter+5.8%
- Vanguard Capital ManagementIn the quarter+1.8%
- State StreetIn the quarter+7.8%
- Tang Capital ManagementIn the quarter
- Dimensional Fund AdvisorsIn the quarter+17%
- American Century CompaniesIn the quarter+200%
- Arrowstreet Capital, Limited PartnershipIn the quarter-0.4%
- Global Alpha Capital ManagementIn the quarter+54%
- Geode Capital ManagementIn the quarter+9.6%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 2.96M | +7.7% | $245M |
| Soleus Capital Management | 867.8K | +5.8% | $72M |
| Vanguard Capital Management | 838.2K | +1.8% | $69M |
| State Street | 831.6K | +7.8% | $69M |
| Tang Capital Management | 707.5K | $59M | |
| Dimensional Fund Advisors | 623.5K | +17% | $52M |
| American Century Companies | 574.5K | +200% | $48M |
| Arrowstreet Capital, Limited Partnership | 562.0K | -0.4% | $47M |
| Global Alpha Capital Management | 558.0K | +54% | $46M |
| Geode Capital Management | 536.4K | +9.6% | $44M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do ANI Pharmaceuticals's filings show?
Who buys and sells is one part of ANI Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have ANIP's insiders bought or sold?
From Jun 9, 2026 to Nov 18, 2026 ANI Pharmaceuticals's insiders bought 0 and sold $3.9M of shares on the market. 94% of the sales were under set 10b5-1 plans.
Which well-known managers hold ANIP?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $18M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.